Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

Small GTPases - Ras and Rho

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Conservative Site-specific Recombination and Phase Variation

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mechanistic insights into evolution of bioluminescence from luciferyl-adenylate chemiluminescence.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2026

Same author

Engineered N-TIMP2 Variant Specifically Targeting MMP-9 Exhibits Potent Anti-Glioblastoma Activity.

Biomolecules·2025

Same author

Engineered protein inhibitors for precise targeting of matrix metalloproteinases.

Trends in biochemical sciences·2025

Same author

ProBASS-a language model with sequence and structural features for predicting the effect of mutations on binding affinity.

Bioinformatics (Oxford, England)·2025

Same author

Proximal Co-Translation Facilitates Detection of Weak Protein-Protein Interactions.

International journal of molecular sciences·2024

Same author

Engineered TIMP2 with narrow MMP-9 specificity is an effective inhibitor of invasion and proliferation of triple-negative breast cancer cells.

The Journal of biological chemistry·2024

Same journal

Retraction: Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression.

Oncotarget·2026

Same journal

TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer.

Oncotarget·2026

Same journal

Retraction: MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2.

Oncotarget·2026

Same journal

Laryngeal leiomyosarcoma: A rare case report and literature review.

Oncotarget·2026

Same journal

Correction: Postsurgery fluids promote transition of cancer stem cell toendothelial and AKT/mTOR activity contributing to relapse of giant cell tumors of bone.

Oncotarget·2026

Same journal

DHHC3 interferes with antitumor immunity in melanoma cells.

Oncotarget·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 24, 2025

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

Targeting Ras with protein engineering.

Atilio Tomazini¹, Julia M Shifman¹

¹Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel.

|July 3, 2023

Summary

This summary is machine-generated.

Targeting Ras proteins in cancer is challenging. Protein engineering offers a new strategy to inhibit various Ras mutations, overcoming limitations of small-molecule drugs and advancing cancer therapy.

Keywords:

Ras oncogene Ras targeting anti-Ras therapeutics protein design protein engineering

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Inducible and Reversible Dominant-negative DN Protein Inhibition

Inducible and Reversible Dominant-negative DN Protein Inhibition

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jul 24, 2025

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Inducible and Reversible Dominant-negative DN Protein Inhibition

Inducible and Reversible Dominant-negative DN Protein Inhibition

Published on: January 7, 2019

Area of Science:

Oncology
Molecular Biology
Drug Discovery

Background:

Ras proteins are key regulators of cell growth, and their mutations drive cancer development.
Targeting Ras proteins with small molecules is difficult due to their structure, though some success has been achieved with specific mutants.
Existing therapies often target only the Ras G12C mutant, leaving other oncogenic Ras variants untreatable with similar methods.

Purpose of the Study:

To explore protein engineering as a novel strategy for targeting diverse Ras oncogenic mutants.
To review recent advancements in engineered anti-Ras agents and their therapeutic mechanisms.
To highlight the potential of protein engineering in overcoming challenges in Ras-targeted cancer therapy.

Main Methods:

Review of scientific literature on Ras protein function, mutations, and targeted therapies.
Analysis of protein engineering approaches, including engineered antibodies, effectors, and binding domains.
Examination of strategies employed by engineered proteins to inhibit Ras activity.
Assessment of advancements in intracellular protein delivery systems.

Main Results:

Protein engineering enables the development of agents with high affinity and specificity for various Ras surfaces.
Engineered proteins can inhibit Ras by disrupting effector interactions, dimerization, or nucleotide exchange.
Other strategies include promoting tumor suppressor interactions or Ras degradation.
Advances in intracellular delivery facilitate the cytoplasmic delivery of these engineered agents.

Conclusions:

Protein engineering presents a versatile and promising approach to target a broader spectrum of Ras mutations in cancer.
This strategy overcomes the limitations of current small-molecule inhibitors, particularly for non-G12C mutants.
Successful intracellular delivery of engineered proteins opens new avenues for developing effective anti-cancer therapeutics against challenging targets like Ras.